Trials / Completed
CompletedNCT00479505
Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder
A Multi-Center, Randomised, Parallel Group, Double-Blind, Placebo Controlled Estimation Study To Assess The Efficacy And Safety Of Modified Release UK-369,003 In The Treatment Of Men With Storage Lower Urinary Tract Symptoms (LUTS) With And Without Erectile Dysfunction (ED).
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 275 (estimated)
- Sponsor
- Pfizer · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a 12 week study in which different doses of UK-369,003 will be administered to patients with a diagnosis of overactive bladder. Patients will complete a series of questionnaires before treatment, during treatment and after treatment, to assess whether UK-369,003 has improved their symptoms of overactive bladder and erectile function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | UK-369,003 | UK-369,003 100mg, 50mg, 25mg and 10mg doses in addition to placebo. |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2007-05-28
- Last updated
- 2011-03-23
Locations
52 sites across 16 countries: Australia, Canada, Chile, Colombia, Finland, France, Germany, Greece, Italy, Latvia, Norway, Poland, Slovakia, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00479505. Inclusion in this directory is not an endorsement.